- Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal The Wall Street Journal
- Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis
- This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. Barron’s
- Novartis to buy Tourmaline Bio, gaining promising heart medicine statnews.com
- Novartis spends $1.4B for Tourmaline and cardiovascular med that impressed in phase 2 Fierce Biotech
Source link
